RankAlpha logo
Back to Rankings

GILD

Gilead SciencesA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Earnings surprise screen
43Non-qualifying2026-10-29 amc

Gilead has a confirmed October 29 report date, strong recent product-demand themes, and a record of frequent EPS and revenue beats, but available checks did not establish positive current-quarter EPS revisions or a credible revenue-upside signal; the recent tape also lacks a confirmed 1.5x-volume accumulation day and a close-location above 0.75 in the latest session. The evidence does not meet the required pre-earnings setup checks.

Revision
0
Revenue
5
Business
12
Price
12
Volume
4
Risk
10
Required signals: None marked positive
Preferred signals: None marked positive
Risk flags: No verified positive current-quarter EPS revision, ESP, or whisper-gap data., No quantified positive revenue estimate revision/upside indicator verified.
Screen as of 2026-10-26. Window 2026-10-26 to 2026-10-30.

Setup hits (3d)

Net Neutral

0 setup hits in the last 3 trading days, 0 bullish, 0 bearish, net strength weak.

Review the highest-weight setup hits and confirm with price action before acting.

Total Hits
0
Last 3d
Bullish
0
0% of hits
Bearish
0
0% of hits
Net Bias
Net Neutral
Balanced
Top Strength
weak
Weighted strength
Bullish setup hits
Sorted by strength

No setup hits found in the last 3 trading days.

Recent setup history
Date
Bullish
Bearish
Total
10.25
Latest
0
0
0
10.24
1d ago
0
0
0
10.23
2d ago
0
0
0
Bullish hitBearish hit- No activity
Open full setup hits view

Setup hits are derived from RankAlpha screener rules firing within the last 3 trading days. Net bias reflects the weighted balance of bullish vs bearish hits.